Ortin Laboratories Ltd - 539287 - PCS Certificate For Transfer/Transmission/Transposition
PCS Certificate for Transfer/Transmission/Transposition29-04-2021
29-04-2021
Ortin Laboratories Ltd - 539287 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate u/r 74(5) of SEBI (DP) Regulations, 201829-04-2021
Ortin Laboratories Ltd - 539287 - Shareholding for the Period Ended March 31, 2021
Ortin Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here20-04-2021
Ortin Laboratories Ltd - 539287 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Nitesh Kumar SharmaDesignation :- Company Secretary and Compliance Officer20-04-2021
Ortin Laboratories Ltd - 539287 - Clarification On Price Movement
Clarification on Price Movement20-04-2021
Ortin Laboratories Ltd - 539287 - Clarification sought from Ortin Laboratories Ltd
The Exchange has sought clarification from Ortin Laboratories Ltd on April 20, 2021 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.20-04-2021
Ortin Laboratories Ltd - 539287 - Closure of Trading Window
Closure of trading window for the quarter ended 31.03.202130-03-2021
Ortin Laboratories Ltd - 539287 - Unaudited Financial Results For The Quarter Ended 31.12.2020
Unaudited Financial Results for the Quarter ended 31.12.202013-02-2021
Ortin Laboratories Ltd - 539287 - Board Meeting Intimation for Un-Audited Financial Results For The Quarter Ended 31.12.2020
Ortin Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2021 ,inter alia, to consider and approve Un-audited financial results for the quarter ended 31.12.202029-01-2021